v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenues:    
Revenues $ 432 $ 143
Cost of revenues:    
Total cost of revenues 42 11
Gross profit 390 132
Operating expenses    
Selling, general and administrative 2,559 3,485
Research and development 149 103
Acquired in-process research and development 0 119
Total operating expenses 2,708 3,707
Operating loss (2,318) (3,575)
Other income (expense), net    
Interest income 2 18
Change in fair value of royalties payable due to related parties 0 (1,163)
Change in fair value of minority equity interest (2,302) 0
Change in fair value of deferred consideration 2,877 0
Other expenses, net (5) 0
Total other income (expense), net 453 (1,194)
Loss from operations before income tax benefit (1,865) (4,769)
Income tax benefit 175 724
Net loss (1,690) (4,045)
Less: Net loss attributable to non-controlling interest (9) 0
Net loss attributable to Catheter Precision, Inc. (1,681) (4,045)
Deemed dividend on warrant inducement offer (1,360) 0
Net loss attributable to Catheter Precision, Inc. common stockholders $ (3,041) $ (4,045)
Net loss per share attributable to Catheter Precision, Inc. common stockholders, basic and diluted (in dollars per share) $ (1.39) $ (6.81)
Weighted-average common shares used in computing net loss per share, basic and diluted (in shares) 2,191,831 593,890
Nonrelated Party [Member]    
Other income (expense), net    
Interest expense $ (76) $ (4)
Related Party [Member]    
Other income (expense), net    
Interest expense (43) (45)
Product [Member]    
Revenues:    
Revenues 248 143
Cost of revenues:    
Total cost of revenues 31 11
Service [Member]    
Revenues:    
Revenues 184 0
Cost of revenues:    
Total cost of revenues $ 11 $ 0